Skip to main content

Technology & Innovation

Ubicquia Launches Next-Gen AI Streetlighting Suite to Accelerate Smart Infrastructure

Image
Ubicquia Launches Next-Gen AI Streetlighting Suite to Accelerate Smart Infrastructure

SHERIDAN, WYOMING - December 4, 2025 - Ubicquia has unveiled a coordinated next-generation smart streetlighting portfolio built around its new UbiCell® Micro controller, major enhancements to the UbiVu® infrastructure management platform and the launch of UbiScout™, an AI video accessory that turns existing streetlights into multi-purpose urban sensors for safety, mobility and energy efficiency.

Integrated portfolio targets utilities and cities under pressure to modernize

With grid operators and municipalities facing rising energy costs, decarbonization targets and aging infrastructure, Ubicquia's new offering is designed to make large-scale modernization of streetlighting networks faster and more manageable. The company positions the portfolio as a way to deliver asset intelligence, remote control and AI analytics without wholesale replacement of installed luminaires.

Norwegian Equips 737-800 Fleet with VCT Finlets to Boost Fuel Efficiency and Cut CO₂

Image
Norwegian Equips 737-800 Fleet with VCT Finlets to Boost Fuel Efficiency and Cut CO₂

SHERIDAN, WYOMING - December 4, 2025 - Vortex Control Technologies (VCT) has signed a fleet-wide retrofit agreement with Norwegian to equip all Boeing 737-800 aircraft with its patented Finlet fuel-saving modification, aligning the Nordic carrier's cost discipline with a more aggressive sustainability strategy in short- and medium-haul aviation.

Aerodynamic retrofits move from trial to fleet standard

Under the new agreement, Norwegian will install VCT Finlets across its entire 737-800 fleet, following in the footsteps of early adopters such as Avelo Airlines, SunExpress and the U.S. Air Force. The deal marks a pivot from pilot programs to full-fleet deployment, signaling growing confidence among operators that incremental aerodynamic improvements can deliver material savings at scale.

AGC Biologics and ATUM Link Up to Speed Cell Line Development for Complex Biologics

Image
AGC Biologics and ATUM Link Up to Speed Cell Line Development for Complex Biologics

SHERIDAN, WYOMING - December 3, 2025 - AGC Biologics is expanding its Cell Line Development Center of Excellence through a new partnership with ATUM, integrating the Leap-In Transposase® expression platform to help biopharma developers move monoclonal antibodies and complex next-generation biologics into the clinic faster and more cost-effectively.

New options for faster, more flexible cell line development

As pressure grows to launch high-value biologics at lower cost, drug sponsors are looking for cell line development (CLD) solutions that combine speed, robustness and scalability. AGC Biologics' collaboration with ATUM adds a modern transposase-based expression platform to its CLD toolkit, creating a menu of fit-for-purpose options for standard monoclonals, multi-specific antibodies and other complex molecules.

AGC Biologics to Scale AAVantgarde's Dual-Vector Gene Therapies for Inherited Retinal Blindness

Image
AGC Biologics to Scale AAVantgarde’s Dual-Vector Gene Therapies for Inherited Retinal Blindness

SHERIDAN, WYOMING - December 3, 2025 - AGC Biologics has signed a new manufacturing agreement with AAVantgarde Bio to produce dual-vector AAV gene therapies for Stargardt disease and retinitis pigmentosa, positioning its BravoAAV™ platform at the center of next-generation treatments for inherited retinal disorders with no approved therapies.

Dual-vector AAV platform targets previously "untreatable" retinal genes

Under the deal, AGC Biologics will provide GMP manufacturing for AAVantgarde's two clinical-stage candidates: AAVB-039 for Stargardt disease, the most common inherited form of macular degeneration in children and young adults, and AAVB-081 for retinitis pigmentosa caused by Usher syndrome type 1B. Both programs are in Phase 1/2 trials, with AAVB-039 being tested in the U.S., UK and Europe, and AAVB-081 representing the first-ever dual AAV gene therapy in an ocular indication.

AGC Biologics and Repair Biotechnologies Join Forces on mRNA Therapy Targeting Atherosclerotic Cardiovascular Disease

Image
AGC Biologics and Repair Biotechnologies Join Forces on mRNA Therapy Targeting Atherosclerotic Cardiovascular Disease

SHERIDAN, WYOMING - December 3, 2025 - AGC Biologics has signed a strategic development and manufacturing agreement with Repair Biotechnologies to advance a novel mRNA therapeutic aimed at rapidly stabilizing and shrinking atherosclerotic plaques, addressing what both partners describe as the leading single cause of human mortality worldwide.

Targeting plaque biology in a high-burden cardiovascular market

The collaboration focuses on an mRNA-based therapy designed to stabilize and reduce atherosclerotic plaques in major blood vessels, directly tackling the root pathology behind heart attacks and strokes. Rupture of unstable plaque and subsequent thrombotic events account for an estimated 27% of all human deaths, underscoring the strategic importance of any technology capable of reversing or halting plaque progression.

AGC Biologics and Rarity PBC Join Forces to Industrialize Gene Therapy for "Bubble Baby" ADA-SCID

Image
AGC Biologics and Rarity PBC Join Forces to Industrialize Gene Therapy for “Bubble Baby” ADA-SCID

SHERIDAN, WYOMING - December 3, 2025 - AGC Biologics is partnering with public benefit company Rarity PBC to bring a potentially life-saving gene therapy for Adenosine Deaminase Severe Combined Immunodeficiency (ADA-SCID) through commercial manufacturing and toward FDA approval, underscoring how CDMO collaborations are becoming central to translating academic breakthroughs into scalable rare disease treatments.

From transformational trials to a U.S. commercial pathway

Under the new agreement, AGC Biologics will provide end-to-end development and GMP manufacturing for Rarity's ex vivo autologous gene therapy RDP-101. If approved, RDP-101 would become the first gene therapy commercially available in the United States to reverse ADA-SCID, a rare inherited immunodeficiency that leaves infants dangerously exposed to severe, recurrent infections.

Ricoh Launches Sustainable A3 MFP Line to Support Circular Economy Goals

Image
Ricoh Launches Sustainable A3 MFP Line to Support Circular Economy Goals

SHERIDAN, WYOMING - December 2, 2025 - Ricoh has introduced its new IM Cxx01CE A3 color multifunction series, positioning the IM C2501CE, IM C3501CE and IM C5501CE as a new sustainability benchmark for office print fleets by combining high reuse rates, lower CO₂ footprint and upgraded security with cloud-ready workflows.

Circular-economy design with high reuse and lower CO₂ footprint

Developed explicitly with circular-economy principles in mind, the new IM Cxx01CE models are manufactured using over 86% reused components and deliver a CO₂ footprint reduced by around 50% compared to comparable multifunction systems. By building on existing hardware resources and refreshing them with the latest security and performance elements, Ricoh enables customers to pursue sustainability targets while maintaining familiar functionality and reliability.

Ricoh and Neat Forge Global AV Partnership to Elevate Workplace Collaboration

Image
Ricoh and Neat Forge Global AV Partnership to Elevate Workplace Collaboration

SHERIDAN, WYOMING - December 2, 2025 - Ricoh and Neat have signed a global partnership agreement to deliver integrated, high-end audiovisual solutions for modern workplaces worldwide, combining Neat's AI-driven video devices with Ricoh's AV Managed Services to enhance hybrid collaboration and workplace experience.

Master-level alliance to scale premium meeting experiences

Under the agreement, Neat, a global leader in professional AV and innovative video technology, and Ricoh, a global leading AV integrator, will collaborate at the highest tier of Neat's Global Partner Program-the Mastery level. The partnership is designed to expand Ricoh's portfolio of high-end meeting room solutions and make Neat-powered spaces more accessible across enterprises of all sizes.

Heidelberg Customer Portal Reaches 3,000 Print Shops as Cloud Apps Drive End-to-End Automation

Image
Heidelberg Customer Portal Reaches 3,000 Print Shops as Cloud Apps Drive End-to-End Automation

SHERIDAN, WYOMING - December 2, 2025 - More than 3,000 print service providers worldwide are now using the cloud-based HEIDELBERG Customer Portal as a digital control center for their end-to-end production, underscoring how system integration and workflow automation are becoming decisive competitive factors in the global print and packaging industry.

Cloud platform becomes a digital command center for print plants

Three years after launch, Heidelberger Druckmaschinen AG's (HEIDELBERG) customer portal is evolving into a central hub for managing production, service and commercial processes. Over 7,000 individual users are actively leveraging the platform to digitalize and automate their operations, with a clear focus on improving efficiency, transparency and sustainability.

Swiss Media House Rubmedia Industrializes Short-Run Digital Print with Heidelberg Jetfire 50 and Versafire LV

Image
Swiss Media House Rubmedia Industrializes Short-Run Digital Print with Heidelberg Jetfire 50 and Versafire LV

SHERIDAN, WYOMING - December 2, 2025 - Swiss communications provider rubmedia has commissioned a compact, highly automated Heidelberg digital print line at its new site in Köniz near Bern, combining a Jetfire 50 inkjet system, a Versafire LV toner press and integrated workflow software to industrialize personalized short-run production.

Digital production line anchors new Köniz facility

With around 35 employees, rubmedia positions itself as a media house focused on creative communication solutions for service providers, industry, associations and political customers. As part of an internal transformation project linked to its relocation, the company rethought its production strategy and installed a tightly integrated digital line designed for efficiency, quality and automation.